Two Sigma Advisers’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-14,132
| Closed | -$24.7K | – | 2493 |
|
|
2024
Q4 | $24.7K | Buy |
14,132
+300
| +2% | +$559 | ﹤0.01% | 2318 |
|
|
2024
Q3 | $26.7K | Sell |
13,832
-24,600
| -64% | -$48.2K | ﹤0.01% | 2241 |
|
|
2024
Q2 | $68K | Sell |
38,432
-30,818
| -45% | -$75.3K | ﹤0.01% | 2345 |
|
|
2024
Q1 | $188K | Sell |
69,250
-2,038
| -3% | -$4.92K | ﹤0.01% | 2224 |
|
|
2023
Q4 | $158K | Buy |
71,288
+51,388
| +258% | +$110K | ﹤0.01% | 2274 |
|
|
2023
Q3 | $57.7K | Sell |
19,900
-10,200
| -34% | -$26.7K | ﹤0.01% | 2265 |
|
|
2023
Q2 | $58.1K | Sell |
30,100
-3,700
| -11% | -$7.3K | ﹤0.01% | 2260 |
|
|
2023
Q1 | $65.9K | Sell |
33,800
-5,200
| -13% | -$10.3K | ﹤0.01% | 2424 |
|
|
2022
Q4 | $45.6K | Sell |
39,000
-35,600
| -48% | -$43.8K | ﹤0.01% | 2371 |
|
|
2022
Q3 | $82K | Buy |
74,600
+800
| +1% | +$1.21K | ﹤0.01% | 2333 |
|
|
2022
Q2 | $118K | Buy |
73,800
+3,500
| +5% | +$8.66K | ﹤0.01% | 2370 |
|
|
2022
Q1 | $252K | Buy |
70,300
+3,600
| +5% | +$12.4K | ﹤0.01% | 2304 |
|
|
2021
Q4 | $261K | Sell |
66,700
-94,488
| -59% | -$442K | ﹤0.01% | 2186 |
|
|
2021
Q3 | $1.06M | Sell |
161,188
-25,200
| -14% | -$166K | ﹤0.01% | 1591 |
|
|
2021
Q2 | $1.15M | Sell |
186,388
-485,100
| -72% | -$2.59M | ﹤0.01% | 1574 |
|
|
2021
Q1 | $3.04M | Sell |
671,488
-198,800
| -23% | -$1.09M | 0.01% | 1070 |
|
|
2020
Q4 | $5.22M | Buy |
870,288
+584,274
| +204% | +$3.84M | 0.01% | 799 |
|
|
2020
Q3 | $2.13M | Sell |
286,014
-667,874
| -70% | -$4.61M | 0.01% | 1137 |
|
|
2020
Q2 | $3.83M | Buy |
953,888
+16,800
| +2% | +$58.5K | 0.01% | 904 |
|
|
2020
Q1 | $2.38M | Sell |
937,088
-11,400
| -1% | -$37.5K | 0.01% | 1024 |
|
|
2019
Q4 | $3.3M | Buy |
948,488
+86,400
| +10% | +$304K | 0.01% | 1004 |
|
|
2019
Q3 | $3.99M | Buy |
862,088
+95,500
| +12% | +$752K | 0.01% | 844 |
|
|
2019
Q2 | $9.44M | Sell |
766,588
-8,700
| -1% | -$111K | 0.02% | 604 |
|
|
2019
Q1 | $10.3M | Buy |
775,288
+407,600
| +111% | +$4.3M | 0.03% | 589 |
|
|
2018
Q4 | $3.17M | Buy |
367,688
+247,600
| +206% | +$1.93M | 0.01% | 977 |
|
|
2018
Q3 | $899K | Buy |
120,088
+39,300
| +49% | +$279K | ﹤0.01% | 1539 |
|
|
2018
Q2 | $481K | Buy |
80,788
+25,100
| +45% | +$143K | ﹤0.01% | 1938 |
|
|
2018
Q1 | $325K | Buy |
55,688
+39,788
| +250% | +$261K | ﹤0.01% | 1980 |
|
|
2017
Q4 | $94K | Buy |
15,900
+3,800
| +31% | +$20.8K | ﹤0.01% | 2152 |
|
|
2017
Q3 | $61K | Buy |
12,100
+1,500
| +14% | +$6.3K | ﹤0.01% | 2144 |
|
|
2017
Q2 | $43K | Sell |
10,600
-2,088
| -16% | -$9.9K | ﹤0.01% | 2215 |
|
|
2017
Q1 | $72K | Buy |
+12,688
| New | +$80.4K | ﹤0.01% | 2295 |
|
|
2014
Q1 | – | Sell |
-76,988
| Closed | -$2.95M | – | 2408 |
|
|
2013
Q4 | $2.95M | Sell |
76,988
-18,400
| -19% | -$542K | 0.03% | 565 |
|
|
2013
Q3 | $2.09M | Buy |
95,388
+53,200
| +126% | +$1.05M | 0.02% | 621 |
|
|
2013
Q2 | $736K | Buy |
+42,188
| New | +$740K | 0.01% | 1047 |
|
Other funds holding LAB
CC
LFCM
TM
MFS
Two Sigma Advisers's LAB Position: Q1 2025 in Review
Two Sigma Advisers sold out of Standard BioTools (LAB) in Q1 2025, closing a stake of 14,132 shares — an estimated $24.7K sold.
Two Sigma Advisers first reported a position in LAB in Q2 2013 and held it in 35 quarters. The position peaked at $10.3M in Q1 2019. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2025.
- Two Sigma Advisers reported no remaining Standard BioTools position as of Q1 2025 after selling out during the quarter.
- Two Sigma Advisers sold 14,132 Standard BioTools shares in Q1 2025, an estimated $24.7K.
- Two Sigma Advisers first reported a position in Standard BioTools in Q2 2013 and held it in 35 quarters.
- Two Sigma Advisers's Standard BioTools position peaked at $10.3M in Q1 2019.
- 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2025.
Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.